Reza Akhavan-Sigari

Dr. Reza Akhavan-Sigari


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
MNMarzieh Nikoo
Marzieh Nikoo
FRFatemeh Rabiee
Fatemeh Rabiee
HMHossein Mohebbi
Hossein Mohebbi
NENegar Eghbalifard
Negar Eghbalifard
HRHamid Rajabi
Hamid Rajabi
RAReza Akhavan-Sigari
Reza Akhavan-Sigari

6 July 2023 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
AMAlireza Mafi
Alireza Mafi
RMReza Mannani
Reza Mannani
SKShayan Khalilollah
Shayan Khalilollah
NHNeda Hedayati
Neda Hedayati
RSRaziyeh Salami
Raziyeh Salami
RAReza Akhavan-Sigari
Reza Akhavan-Sigari

10 December 2022 in Biosensors
Verified
Journal Article
Open access
PDF file
Mahmood BaraniMahmood Barani
Mahmood Barani
HFHadis Fathizadeh
Hadis Fathizadeh
HAHassan Arkaban
Hassan Arkaban
DKDavood Kalantar-Neyestanaki
Davood Kalantar-Neyestanaki
MAMajid Reza Akbarizadeh
Majid Reza Akbarizadeh
RAReza Akhavan-Sigari
Reza Akhavan-Sigari
Klebsiella pneumoniae is an important human pathogen that causes diseases such as urinary tract infections, pneumonia, bloodstream infections, bacteremia, and sepsis. The rise of multidrug-resistant strains has severely limited the available treatments for K. pneumoniae infections. On the other hand, K. pneumoniae activity (and related infections) urgently requires improved management strategies. A growing number of medical applications are using nanotechnology, which uses materials with atomic or molecular dimensions, to diagnose, eliminate, or reduce the activity of different infections. In this review, we start with the traditional treatment and detection method for K. pneumoniae and then concentrate on selected studies (2015–2022) that investigated the application of nanoparticles separately and in combination with other techniques against K. pneumoniae.

10 August 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
MSMohamed Saadh
Mohamed Saadh
MAMeryelem Tania Churampi Arellano
Meryelem Tania Churampi Arellano
RSRavinder S Singh
Ravinder S Singh
Ali Hassan AminAli Hassan Amin
Ali Hassan Amin
NSNidhi Sharma
Nidhi Sharma
RAReza Akhavan-Sigari
Reza Akhavan-Sigari

23 September 2016 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
DMDorothee Mielke
Dorothee Mielke
RAReza Akhavan-Sigari
Reza Akhavan-Sigari
VRVeit Rohde
Veit Rohde
KEKajetan L. von Eckardstein
Kajetan L. von Eckardstein
Background and Study Aims In microvascular decompression of the trigeminal nerve for trigeminal neuralgia (TN), the site of conflict is occasionally difficult to identify. Endoscopy has been described to better evaluate the anatomical conflict in such situations. We hypothesized that indocyanine green (ICG) angiography could allow for better visualization of the compressing artery and its anatomical relation to the nerve. Material and Methods ICG angiography was performed in 17 TN patients undergoing microvascular decompression. We focused on whether ICG angiography is helpful in determining the site of conflict, particularly when not directly visible via the microscope, and whether fluorescence is strong enough to shine through the nerve obliterating the direct view of the compressing vessel. Results In four patients, the site of conflict was immediately apparent after opening the cerebellopontine cistern, and ICG angiography did not provide the neurosurgeon with additional information. In another two patients, imaging quality and fluorescence were too poor. Of the remaining 11 patients with a hidden site of nerve–vessel conflict, ICG angiography was found to be helpful in anticipating the site of compression and the course of the artery in 7 patients, particularly in regard to the so-called shining-through effect through fiber bundles of the thinned nerve. Of all the patients, 88% reported at least improvement or cessation of their symptoms, including all of the patients with a shine-through effect. Conclusion ICG angiography could be a helpful adjunct in decompressing the trigeminal nerve and can guide the surgeon to the nerve–vessel conflict. Intensity of the fluorescence is powerful enough to shine through thinned and splayed trigeminal nerve fiber bundles.

1 January 2021 in Molecular & Cellular Biomechanics
Verified
Journal Article
Open access
FRFatemeh Rahbar
Fatemeh Rahbar
AFAvid Farhang Fagheh
Avid Farhang Fagheh
AKAyda Khosravi
Ayda Khosravi
SSSiavash Shariatzadeh
Siavash Shariatzadeh
RAReza Akhavan-Sigari
Reza Akhavan-Sigari
The protein ERp57 is a stress-responsive protein, mainly exists in the endoplasmic reticulum (ER), and a small amount in the cell membrane, cytoplasm, nucleus and mitochondria, which is involved in the signal transduction from the cell surface, the regulation process that occurs in the nucleus, and the formation of polymer protein complexes involved in DNA repair. Various degrees of ERp57 dysregulation has been observed in many types of non-communicable diseases especially in cancers. Previous studies showed that the expression of ERp57 could play a key role in occurrence and development of cancers such as breast cancer, gastric cancer, ovarian cancer, etc.; in addition, it has been suggested to play a pivotal role in disease progression of non-cancerous diseases such as neurodegeneration, liver disease, kidney disease, intestinal irritability syndrome and airway hypersensitivity. Thus, abnormal expression of ERp57 could be used as promising biomarker for cancer diagnosis and prognosis based on the previous studies. In this regard, current study was aimed to review the literature, which have been elucidate the role of ERp57 protein expression in both non-cancer and cancer disease. Overall, most studies have shown that inhibiting/knocking out of ERp57 could inhibit the cell proliferation and also induce apoptosis in both human cancerous and non-cancerous cells. Also, it has been suggested that the overexpression of ERp57 could intensify the cancer development. Therefore, it could be hypothesized that targeting of ERp57 might be a potential treatment in cancerous and non-cancerous diseases.